BK0975 Medical Beauty
- 1165.785
- +1.262+0.11%
Amex (300896): The quarterly report is in line with expectations and shows growth resilience
Incident description The company released its 2024 quarterly report. 2024Q1 achieved operating income of 808 million yuan, a year-on-year increase of 28%, realized net profit of 527 million yuan, a year-on-year increase of 27%, and realized net profit deducted from non-mother 5
Bloomage BioTechnology Corporation Limited Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Bloomage BioTechnology Corporation Limited (SHSE:688363), which a week ago released some disappointing yearly results that could have a notable impact on how t
Huaxi Biotech (688363): Q1 performance improved markedly, medical and aesthetic business continued to grow
Core view: Incident: The company released an annual report and a quarterly report. In 2023, it achieved revenue of 6.076 billion yuan, a year-on-year decrease of 4.45%; net profit to mother was 593 million yuan, down 38.97% year on year; net profit after deducting net profit
Aimeike (300896): Performance is in line with expectations, new product releases are expected
Investment Highlights 24Q1 profit was basically in line with the median performance forecast. After deducting non-net profit, the same increase was 37%. 24Q1: Revenue/net profit attributable to mothers/net profit deducted from non-net profit were $808/5.27/528 million, respectively, an increase of 28%/27%/
Huaxi Biotech (688363): The inflection point in profitability in the first quarter showed leading growth in the medical terminal business
Revenue growth was steady in the first quarter of 2024, and net profit to mother increased 21%. The company's revenue in 2023 was 6.076 billion yuan, -4.45% year-on-year, and net profit to mother was 593 million yuan, or -38.97% year-on-year.
Huaxi Biotech (688363): Q1 surpassed expectations, high medical and aesthetic growth and significant cost reduction
Guide to this report: The company's performance in 2023 was under pressure. The 24Q1 improvement was obvious, and profit recovery exceeded expectations. The main reason was that high growth in medicine and beauty led to structural optimization of profit margins. At the same time, the medical, aesthetic and skincare sector had remarkable cost control results. Focus on subsequent skincare sector revenue
Express News | 456 companies were surveyed by institutions
Huaxi Biotech (688363) 2023 Annual Report and 2024 Quarterly Report Review: Accelerated growth in the raw materials and medical terminal business is expected to reach an inflection point after adjustments to the skincare business
Incident: Huaxi Biotech revealed its results for the first quarter of 2023 and 2024. In '23, the company achieved revenue of 6.076 billion yuan, -4.45% year on year; net profit to mother was 593 million yuan, or -38.97% year on year;
Huaxi Biotech (688363): 24Q1 performance gradually improved, looking forward to the results of the company's strategic adjustments
Investment highlights Results for the 2023 adjustment period are under pressure, and 2024Q1 recovery is increasing. In 2023, the company achieved revenue of 6.08 billion yuan (-4.45% year-on-year, same below) and net profit of 590 million yuan (-39.0%) to mother
Huaxi Biotech (688363): Profit picked up in 2024Q1, looking forward to the completion of the company's transformation and revitalization
Incident: In the context of business adjustments in 2023, the 2024Q1 profit side picked up, and the company released an annual report and a quarterly report: achieved revenue of 6.076 billion yuan in 2023 (-4.5% year-on-year, same below) and net return to mother
Huaxi Biology (688363): First seen the dawn in 1Q24 in 24 years or gradually recovered
1Q24 is beginning to see the light of day. I am optimistic about a gradual recovery in 24, with a target price of 80.41 yuan to maintain the “purchase” of Huaxi Biotech's 2023 revenue/net profit attributable to mother/ net profit deducted from non-mother of 60.8/59/49 million
Huaxi Biotech (688363): 24Q1 profit growth exceeded expectations, profit is expected to continue to recover
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 6.076 billion yuan (-4.45%) and net profit to mother of 593 million yuan (-38.97%),
Huaxi Biotech (688363): Continued adjustment of skincare products, medical and aesthetic performance picked up markedly in Q1
Incident: Huaxi Biotech released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 6.076 billion yuan/ -4.45%, net profit to mother of 593 million yuan/ -38.97%, after deducting net income from mother
Huaxi Biotech (688363): The adjustments are showing initial results, but the recovery in performance needs to be further confirmed
In the context of functional skincare business adjustments, Huaxi Biotech's 2023 revenue recorded its first negative growth since launch (-4.5%), and the net profit margin fell to 9.8%, which is basically in line with the 2023 performance report. We are delighted
Aimeike (300896) 2024 Quarterly Report Review: Core Products Drive Growth and Collaborate to Lay Out New Growth Points
Incident: The company achieved operating income of 808 million yuan in 24Q1, +28.24% year over year; net profit to mother of 527 million yuan, +27.38% year over year; net profit after deducting non-return to mother of 528 million yuan, +36.53% year over year
Express News | Huaxi Biotech: Net profit of 243 million yuan in the first quarter increased 21.39% year-on-year
Aimeike (300896): 24Q1 net profit YOY +27.38% performance in line with expectations
Incident Overview The company released its report for the first quarter of 2024. 24Q1 achieved revenue of 808 million yuan, +28.24% year over year; net profit to mother of 527 million yuan, +27.38% year over year; net profit without return to mother 5.28
Aimeike (300896): 2024Q1 Earnings Review: Performance Meets Expectations, Expectations for Core Products to Drive Growth
Incident: The company recently announced its 2024 quarterly report. The 24Q1 revenue was 81 million yuan/+28% year over year, and net profit to mother was 530 million yuan/year over year +27%. The increase in revenue performance was in line with expectations, and the performance was close to the forecast limit (this
Express News | The concept of computing power continues to ferment, and many leading telecommunications companies have received intensive research from institutions
Aimeike (300896): Profitability remains high, and the pipeline is expected to be realized one after another
Guide to this report: Profitability remains high, and is expected to be realized one after another in the research pipeline. It is optimistic about long-term growth space and maintains an increase in holdings rating. Key investment points: Maintain an increase in holdings rating. The company's 2024Q1 revenue was 808 million yuan (+28.24%)